Exalenz Bioscience Ltd.

4 Ha'Maayan Street, 7177872 Modiin

Telephone +972 8 9737500
Fax +972 8 9737501

This company is co-exhibitor of
Israel Export & International Cooperation Institute


Hall map

MEDICA 2016 hall map (Hall 16): stand G40

Fairground map

MEDICA 2016 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases

Auto-immune diseases

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  •  Diagnostics / kits for the gastro enterology

Diagnostics / kits for the gastro enterology

Our products

Product category: Auto-immune diseases, Diagnostics / kits for the gastro enterology


The BreathID Hp is the most innovative next generation Urea Breath Test (UBT) for diagnosing H. pylori infection and for post-treatment monitoring of H. pylori infection in adults. The clinically-proven accurate test is an easy, single-step procedure for the qualitative detection of urease associated with Helicobacter pylori in the human stomach.

BreathID Hp Benefits
>99% sensitivity and specificity greater correlated with a biopsy.
Real-time immediate results right in the office
Compatible to clinic workflow
Begin treatment immediately
Fast, 10-15 minute test
Easy to use with one-touch operation
Reimbursable with established CPT codes
Small footprint
Upload test results to Patient Record System
Generate improved revenue

Hp Detection
UBTs are well-established and accepted as a reliable, non-invasive method for HP detection, and are recommended and endorsed by numerous medical societies as the test of choice for initial detection as well as for post-treatment monitoring testing. BreathID Hp is the only UBT that delivers immediate results. BreathID Hp is FDA cleared in the U.S. and is CE-approved in Europe for diagnosing and treating Hp. BreathID Hp delivers exceptional sensitivity of 100% and specificity of 99.2% -- accuracy that is unmatched compared to traditional H. pylori tests currently available.

Infection of H. pylori is associated with peptic ulcer disease, gastric adenocarcinoma, and mucosa associated lymphoid tissue (MALT) lymphoma. It is estimated that over 2/3 of the world’s population is infected with the bacteria. The World Health Organization categorizes H. pylori as a group I or definite human carcinogen. Over the course of the last few years, testing for H. pylori in symptomatic patients has become standard practice.

More Less

About us

Company details

Exalenz Bioscience Ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient's exhaled breath based on its BreathID technology platform. These products improve the quality of patient care, enhance clinic and medical center efficiencies and fuel revenue generation. Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.

The BreathID technology platform answers the long-standing need for fast, convenient and accurate assessment and monitoring of functional diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient's exhaled breath - continuously, automatically and in real time. BreathID products are designed for mobility and user-friendly operation, and can be performed in the office or clinic.

The company’s flagship Breath ID Hp is an extremely accurate, easy-to-use, self-calibrating urea breath test (UBT) and the emerging gold standard to diagnose, monitor and manage gastric H. pylori bacteria infection. It is estimated that two-thirds of the world's population is infected with H. pylori. Recent studies estimate that more than 90% of duodenal ulcers and 80% of gastric complications are caused by H. pylori, conditions which have been to ultimately lead to stomach cancer and other gastric complications if left untreated.

The design of sophisticated diagnostic systems that are simple to operate is a hallmark of Exalenz. The company conducts ongoing research in collaboration with leading clinical and industrial partners in the U.S., Europe, Asia, and Israel.

Exalenz’ mission is to become a leading provider of accurate, breath test-based, point-of-care disease management solutions for a broad range of GI and liver disorders.

As our name implies, we define "excellence" as successfully meeting patient and practitioner needs. Our technology furthers this goal by providing both medical professionals and patients with advanced solutions and vital diagnostic information.

More Less